Key Highlights:
- HRV Pharma will invest approximately ₹150 crore to expand its capabilities in two high-value, supply-constrained pharmaceutical segments: synthetic peptides and high-potency oncology APIs.
- The company plans to invest ₹40–50 crore to establish dedicated cGMP peptide manufacturing capacity through a strategic capacity underwriting arrangement.
- HRV Pharma will commit approximately ₹100 crore toward a strategic joint venture focused on high-potency oncology APIs and specialised molecules, supporting its complex-molecule portfolio and access to regulated markets.
Implications:
HRV Pharma’s ₹150 crore investment strengthens its position in complex and high-value pharmaceutical segments, particularly synthetic peptides and high-potency oncology APIs. The initiatives are expected to secure dedicated manufacturing capacity, expand the company’s portfolio of complex molecules and accelerate entry into regulated markets while maintaining its asset-light operating model. The focus on supply-constrained technologies also positions HRV Pharma to address growing demand for specialised pharmaceutical manufacturing capabilities.
Source: Express Pharma
